<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unipolar depression in adults: General principles of treating resistant depression</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unipolar depression in adults: General principles of treating resistant depression</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unipolar depression in adults: General principles of treating resistant depression</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Thase, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">K Ryan Connolly, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H771741988"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Many patients presenting with unipolar major depression (major depressive disorder) do not recover after their initial treatment. As an example, one prospective observational study found that among 3671 outpatients who were treated with <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, remission occurred in only 37 percent [<a href="#rid1">1</a>]. In addition, patients who fail their initial treatment often do not respond to subsequent trials and frequently experience chronic depression, impaired psychosocial functioning, and poor overall general health [<a href="#rid2">2</a>].</p><p>This topic reviews the general principles of treating resistant depression. Choosing a specific treatment for resistant depression, and the epidemiology, risk factors, assessment, and prognosis of treatment-resistant depression are discussed separately, as are the initial treatment of depression, and clinical features and diagnosis of depression.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">"Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2484728125"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unipolar major depression</strong> – Unipolar major depression (major depressive disorder)  (<a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">table 1</a>) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania or hypomania [<a href="#rid3">3</a>]. A major depressive episode is a period lasting at least two weeks, with five or more of the following symptoms: depressed mood, anhedonia, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide. Additional information about the clinical presentation and diagnosis of major depressive disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-resistant depression</strong> – The term “treatment-resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized [<a href="#rid4">4,5</a>]. The definition of treatment-resistant depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">"Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis", section on 'Treatment-resistant depression'</a>.)</p><p></p><p class="headingAnchor" id="H1247386365"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H117726559"><span class="h2">Reassess the diagnosis</span><span class="headingEndMark"> — </span>If patients treated for unipolar depression do not respond to initial treatment, they should be re-evaluated to confirm the diagnosis is unipolar depression rather than a different disorder, such as bipolar depression, complicated grief, or substance induced depressive disorder [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1227336655"><span class="h2">Comorbidity</span><span class="headingEndMark"> — </span>Treatment-resistant unipolar major depression is often comorbid with other psychopathology [<a href="#rid6">6</a>]. The therapies recommended for treatment-resistant depression are administered when the depressive syndrome is the primary disorder or when the therapy is compatible with the treatment administered for the comorbid disorder. In addition, a single treatment, such as an antidepressant, may be effective for both treatment-resistant depression and the comorbidity (eg, generalized anxiety disorder). However, treatment of resistant depression may need to be deferred during treatment of a more salient disorder, such as anorexia nervosa.</p><p>The comorbid psychopathology that often occurs in patients with unipolar depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features", section on 'Psychiatric'</a>.)</p><p class="headingAnchor" id="H1719862972"><span class="h2">Assess adherence</span><span class="headingEndMark"> — </span>Many patients with ongoing symptoms of treatment-resistant depression discontinue pharmacotherapy [<a href="#rid8">8</a>]. Clinicians should attempt to identify and address barriers to adequate adherence [<a href="#rid6">6,9</a>]. Improving adherence with pharmacotherapy may convert nonresponders to responders. (See  <a class="medical medical_review" href="/z/d/html/90153.html" rel="external">"Unipolar depression in adults and initial treatment: General principles and prognosis", section on 'Enhancing adherence'</a>.)</p><p class="headingAnchor" id="H1265500655"><span class="h2">Treatment strategies for resistant depression</span><span class="headingEndMark"> — </span>For patients with unipolar major depression who do not respond to initial treatment with an antidepressant medication, treatment strategies include [<a href="#rid10">10-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Augmentation (adding a treatment)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medication (eg, second-generation antipsychotic, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, a second antidepressant, or triiodothyronine)</p><p class="bulletIndent2"><span class="glyph">•</span>Psychotherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Electroconvulsive therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Repetitive transcranial magnetic stimulation</p><p class="bulletIndent2"><span class="glyph">•</span>Supplementary and supportive interventions such as exercise</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Switching treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Different antidepressant</p><p class="bulletIndent2"><span class="glyph">•</span>Psychotherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Electroconvulsive therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Repetitive transcranial magnetic stimulation</p><p></p><p>Choosing a specific treatment for resistant depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="headingAnchor" id="H544799708"><span class="h2">Nonspecific care management</span><span class="headingEndMark"> — </span>Patients with treatment-resistant depression who are receiving a specific therapy may benefit from nonspecific care management, in which clinicians [<a href="#rid18">18,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Educate patients and families about:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Depression, including signs, symptoms  (<a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">table 1</a>), and prognosis (see  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/14693.html" rel="external">"Unipolar depression in adults: Course of illness"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suicide (see  <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment options (see  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Good sleep practices, including sleep hygiene  (<a class="graphic graphic_table graphicRef71116" href="/z/d/graphic/71116.html" rel="external">table 2</a>), stimulus control  (<a class="graphic graphic_table graphicRef77189" href="/z/d/graphic/77189.html" rel="external">table 3</a>), and sleep restriction  (<a class="graphic graphic_table graphicRef69303" href="/z/d/graphic/69303.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">"Overview of the treatment of insomnia in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regularly review and quantify depressive symptoms (see <a class="local">'Measurement based care'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review and manage side effects</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review occupational and interpersonal functioning</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide a 24-hour on-call service.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encourage patients to persist with treatment. We reassure patients that we will not abandon them and will try to help them get better as long as they are willing to work with us.</p><p></p><p>The relationship between clinicians and patients may affect treatment outcomes independent of the specific treatment that is administered, but the effect is relatively small. In a randomized trial that compared <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a> with placebo in 112 patients with unipolar major depression (not selected for treatment resistance), approximately 8 percent of the variability in outcome was due to the specific treating psychiatrist, separate from the study treatment [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H744149176"><span class="h3">Measurement based care</span><span class="headingEndMark"> — </span>Measurement based care is the systematic, quantitative assessment of symptoms that is typically performed at each visit. Psychosocial functioning, quality of life, treatment adherence, and tolerability of treatment can also be measured.</p><p>The nine-item Patient Health Questionnaire is a self-report, standardized depression rating scale  (<a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">table 5</a>) that measures the frequency of symptoms as a proxy for severity and is widely used to ascertain response to treatment [<a href="#rid21">21,22</a>]. Scores &gt;20 indicate severe depression, whereas scores &lt;5 indicate remission. A decrease ≥50 percent generally indicates a clinically significant response.</p><p>Additional information about measurement based care, including the Patient Health Questionnaire, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)"</a>.)</p><p class="headingAnchor" id="H3433235440"><span class="h2">Duration of an adequate trial</span><span class="headingEndMark"> — </span>We generally treat unipolar major depression for 6 to 12 weeks before deciding whether a regimen has sufficiently relieved symptoms [<a href="#rid8">8,23,24</a>]. However, for patients who show little improvement (eg, reduction of baseline symptoms ≤25 percent) after four to six weeks, we administer next-step treatment [<a href="#rid25">25,26</a>]. Additional information about the duration of an adequate treatment trial is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment", section on 'Duration of an adequate trial'</a>.)</p><p class="headingAnchor" id="H3271408461"><span class="h2">Referral</span><span class="headingEndMark"> — </span>Most depressive episodes are initially treated by internists and primary care clinicians [<a href="#rid27">27,28</a>], and second-step treatment for resistant depression is often provided by these clinicians as well, rather than psychiatrists [<a href="#rid29">29</a>]. In one study, patients (n = 727) who did not respond to initial treatment with <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> were randomly assigned to next-step treatment; the probability of remission in primary care and psychiatric settings was similar (odds ratio 1.0) [<a href="#rid30">30</a>].</p><p>However, referral to a mental health specialist should be considered for depressive episodes that are unresponsive to multiple (eg, two to four) next-step treatment trials [<a href="#rid6">6,8,29</a>]. In addition, referral is generally indicated for severe major depression characterized by suicidal or homicidal ideation or behavior, psychosis, or catatonia. (See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Severe depression'</a>.)</p><p class="headingAnchor" id="H3623708775"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H3668032180"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with unipolar major depression who do not respond to initial treatment with an antidepressant medication, treatment strategies include augmentation and switching. (See <a class="local">'Treatment strategies for resistant depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with treatment-resistant depression who are receiving a specific therapy may also benefit from nonspecific care management, such education and monitoring. (See <a class="local">'Nonspecific care management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally treat unipolar major depression for 6 to 12 weeks before deciding whether a regimen has sufficiently relieved symptoms. However, for patients who show little improvement (eg, reduction of baseline symptoms ≤25 percent) after four to six weeks, we administer next-step treatment. (See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment", section on 'Duration of an adequate trial'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Referral to a mental health specialist is often made for treatment-resistant depression that does not respond to multiple next-step treatment trials, as well as severe major depression. (See <a class="local">'Referral'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.</a></li><li><a class="nounderline abstract_t">Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry 2005; 66 Suppl 8:5.</a></li><li><a class="nounderline abstract_t">Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs 2009; 23:627.</a></li><li><a class="nounderline abstract_t">McLachlan G. Treatment resistant depression: what are the options? BMJ 2018; 363:k5354.</a></li><li><a class="nounderline abstract_t">Malhi GS, Das P, Mannie Z, Irwin L. Treatment-resistant depression: problematic illness or a problem in our approach? Br J Psychiatry 2019; 214:1.</a></li><li><a class="nounderline abstract_t">Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164:201.</a></li><li><a class="nounderline abstract_t">Rush AJ, Thase ME. Improving Depression Outcome by Patient-Centered Medical Management. Am J Psychiatry 2018; 175:1187.</a></li><li><a class="nounderline abstract_t">Malhi GS, Adams D, Porter R, et al. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl 2009; :8.</a></li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.</a></li><li class="breakAll">American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).</li><li class="breakAll">Trangle M, Dieperink B, Gabert T, et al. Institute for Clinical Systems Improvement. Major Depression in Adults in Primary Care. Updated May 2012. http://www.icsi.org/depression_5/depression__major__in_adults_in_primary_care_3.html (Accessed on December 12, 2012).</li><li><a class="nounderline abstract_t">Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61:540.</a></li><li class="breakAll">National Institute for Health &amp; Clinical Excellence. The Treatment and Management of Depression in Adults (updated edition). National Clinical Practice Guideline 90, 2010. http://www.nice.org.uk/ (Accessed on December 24, 2018).</li><li><a class="nounderline abstract_t">Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29:459.</a></li><li><a class="nounderline abstract_t">Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatry 2016; 61:561.</a></li><li><a class="nounderline abstract_t">Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.</a></li><li><a class="nounderline abstract_t">Reynolds CF 3rd, Dew MA, Martire LM, et al. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. Int J Geriatr Psychiatry 2010; 25:1134.</a></li><li><a class="nounderline abstract_t">McKay KM, Imel ZE, Wampold BE. Psychiatrist effects in the psychopharmacological treatment of depression. J Affect Disord 2006; 92:287.</a></li><li><a class="nounderline abstract_t">Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.</a></li><li><a class="nounderline abstract_t">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.</a></li><li><a class="nounderline abstract_t">Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70 Suppl 6:16.</a></li><li><a class="nounderline abstract_t">Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53:649.</a></li><li><a class="nounderline abstract_t">McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry 2010; 71 Suppl 1:16.</a></li><li><a class="nounderline abstract_t">Kudlow PA, McIntyre RS, Lam RW. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs 2014; 28:601.</a></li><li><a class="nounderline abstract_t">Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010; 67:1265.</a></li><li><a class="nounderline abstract_t">Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. J Clin Psychiatry 2008; 69:1064.</a></li><li><a class="nounderline abstract_t">Degruy FV 3rd. A note on the partnership between psychiatry and primary care. Am J Psychiatry 2006; 163:1487.</a></li><li><a class="nounderline abstract_t">Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008; 65:870.</a></li></ol></div><div id="topicVersionRevision">Topic 119986 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074942" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12813115" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12813115" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336031" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Issues in treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19594193" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : STAR*D: revising conventional wisdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30563939" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment resistant depression: what are the options?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30565539" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment-resistant depression: problematic illness or a problem in our approach?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267779" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : STAR*D: what have we learned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30220219" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Improving Depression Outcome by Patient-Centered Medical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356154" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical practice recommendations for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25969470" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486154" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20957693" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16503356" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Psychiatrist effects in the psychopharmacological treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10568646" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The PHQ-9: validity of a brief depression severity measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19922740" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12706951" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis and definition of treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20977871" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : When should you move beyond first-line therapy for depression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24831418" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Early switching strategies in antidepressant non-responders: current evidence and future research directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135326" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : National trends in the treatment for depression from 1998 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18399725" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A note on the partnership between psychiatry and primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678792" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
